GlassScriptPhysician profile
Charles B Nemeroff
NPI 1326228347
$428,591.08
in general payments reported to CMS, 2019-2025
20 companies · $63K in 2025
The $63K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.11 · 2020: $27K · 2021: $65K · 2022: $89K · 2023: $109K · 2024: $76K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $213K · Honoraria: $21K · Travel and Lodging: $11K · Food and Beverage: $2,164 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $213,090.00 |
| Honoraria | $21,150.00 |
| Travel and Lodging | $11,230.17 |
| Food and Beverage | $2,163.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $208,261.64 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145,000.00 | 2020-2025 | Caplyta |
| H. Lundbeck A S | $16,400.00 | 2021-2025 | Rexulti |
| Mylan INC. | $10,060.79 | 2023 | |
| Janssen Scientific Affairs, LLC | $9,565.00 | 2023-2024 | |
| Livanova USA, INC. | $8,228.39 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Acadia Pharmaceuticals INC | $7,429.17 | 2020-2024 | |
| Sk Life Science, INC. | $4,800.00 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $3,500.00 | 2025 | |
| Almatica Pharma LLC | $3,254.54 | 2022-2025 | Loreev Xr |
| Bioxcel Therapeutics, INC. | $2,680.00 | 2023 | Igalmi |
| Alfasigma USA, INC. | $2,447.50 | 2021 | |
| Abbvie INC. | $2,400.00 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,991.30 | 2022-2025 | Rexulti |
| Corcept Therapeutics | $1,425.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,000.00 | 2020 | |
| Tris Pharma INC | $64.66 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.99 | 2023 | |
| Biogen, INC. | $28.65 | 2022 | |
| Janssen Research & Development, LLC | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Nemeroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.